Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery

• Status: Unknown status
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

Surgery, perioperative stress, anaesthetics and analgesics may modulate the immunosurveillance mechanisms and overwhelm host defences that normally maintain a balance between immunity & carcinogenesis. This may lead to escape of cancer cells and tilt the scales toward a more protumorigenic microenvironment. Volatile agents, in particular, have been shown to exhibit profound immunosuppressive effects. In comparison, propofol has a favorable profile and inhibits cancer cell activity. Determining "cancer-protective" role of TIVA with propofol presents an exciting window of opportunity that has potential to improve outcomes in cancer patients undergoing resection surgery

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tata Memorial Centre
• Treatments: Anesthetics; Atracurium; Citric Acid; Ether; Fentanyl; Propofol; Sevoflurane

Criteria

Inclusion Criteria:

1. Women with histopathologically (biopsy/FNAC) proven breast carcinoma with Resectable disease (T 1-4, N 0-1, M 0) [Stage I-III].

2. Willing for upfront modified radical mastectomy.

3. ASA Physical Status 1-2

Exclusion Criteria:

1. use of morphine or on steroid therapy upto 3 months before surgery;

2. history of substance abuse or cognitive dysfunction;

3. endocrine disorders- diabetes, hypothyroid;

4. history of HIV, Hep-B or Hep-C infections;

5. Contraindication to analgesics or anaesthetic drugs;

6. Pregnant & lactating women